People with treatment-resistant depression and/or acute suicidal ideation can find relief from their debilitating symptoms at Star Behavioral Health. The health center provides Spravato ketamine for patients that have not found recovery through traditional forms of treatment. Spravato is the intranasal form of ketamine administration, also known as Esketamine.
Star Behavioral Health is led by Dr. Pamela Ruppel, a psychiatric nurse practitioner. With over two decades of experience, Dr. Ruppel has both the expertise and the compassion to help patients overcome their diseases. She and the team at the mental health center approach each patient as an individual for a truly unique and tailored patient experience. By using breakthrough ketamine therapy along with other forms of traditional mental therapy, Dr. Ruppel has helped many people regain control of their health.
Psychedelic AI is Here! Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!
Offered Treatments
Spravato (Esketamine Nasal Spray)
Treated Conditions
Treatment-Resistant Depression
Star Behavioral Health defines this as failure to have an adequate response to two separate SSRIs and one other antidepressant.
Acute Suicidal Ideation
Important Info
Spravato referrals are accepted at this time, and the process for authorization usually takes about 2-3 weeks at a minimum from the referral date to completely process it with insurance and scheduling. It may be faster depending on insurance response time.
Star Behavioral Health’s office is on the first floor, handicap accessible, and parking is safe, next to the building, and free.
The clinic has a secure patient portal that can be used for confidential questions, advice, and scheduling.
What to Know About Esketamine
Spravato, also known as Esketamine, is taken as a nasal spray and typically prescribed in conjunction with a conventional oral antidepressant, as it may enhance the effect of those drugs.
In 2019, the FDA approved Spravato for patients with major depressive disorder who hadn’t responded to other treatments. A year later, the agency added patients who are having suicidal thoughts or have recently attempted to harm themselves or take their own lives.
The Healing Maps Editorial Team has decades of experience across all facets of the psychedelic industry. From assessing studies and clinic research, to working with clinician's and clinics, we help provide data-backed information to psychedelic-curious individuals across the globe.
Leave a Reply